- Cardiac stents are small mesh tubes inserted into narrowed or blocked coronary arteries to improve blood flow and prevent heart attacks, commonly used in angioplasty.
- The market is witnessing growth due to the rising geriatric population, poor lifestyle habits, and an increase in coronary artery disease cases across Asia-Pacific.
- The China holds the largest market share of 26.78% due to favorable reimbursement policies, technological innovations, and a high number of PCI (percutaneous coronary intervention) procedures.
- China is expected to hold the largest share in the Asia-Pacific cardiac stents market due to its vast population, increasing prevalence of coronary artery disease, and significant investments in healthcare infrastructure. The government’s focus on improving cardiovascular care and the rising adoption of advanced stent technologies further boost market growth.
- India is expected to witness rapid growth during the forecast period, driven by the increasing incidence of cardiovascular diseases, growing healthcare awareness, and expanding urban healthcare facilities. Affordable healthcare services and rising medical tourism also contribute to the market expansion.
- The drug-eluting stents (DES) segment with 43.15% is expected to be the fastest-growing segment in the Asia-Pacific cardiac stents market, driven by its superior clinical outcomes in reducing restenosis and improving long-term vessel patency. Despite the availability of bare-metal stents (BMS) and bioresorbable vascular scaffolds (BVS), DES continues to gain rapid adoption due to ongoing advancements in stent coatings and drug formulations that enhance safety and efficacy. Increasing awareness among cardiologists about the benefits of DES, coupled with expanding healthcare infrastructure and growing patient volumes in countries like China and India, is accelerating its uptake. The segment’s ability to reduce repeat interventions makes it a preferred choice in both urban and emerging markets within the region.
